Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failur... View more
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-8.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
Moltich ME, DeFonzo RA, Franz MJ, Keane WF, Mogensen CE, Parving H-H, et al. Nephropathy in Diabetes. Diabetes Care. 2004;27:S79-83.
AHFS; Drug Information. American Society of Health system Pharmacists, Inc. 7272 Wisconsin Avenue, Bethseda, MD 20814; 2004.
Ilka K, Wollesky C, Kottra G, Hahn M, Fischer W, Zebisch K, et al. Transport of Angiotensin-Converting Enzyme Inhibitors by H+ / Peptide Transporters Revisited. J Pharmacol Exp Ther. 2008;327(2):432-41.
Paediatric Formulary Committee. BNF for Children 2011-2012 (British National Formulary for Children). 2012.
Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. Blackwell Science Ltd; 2005;59(6):674-6.
WHO. Development of Paediatric Medicines: Pharmaceutical Development. Points to Consider. 2008;QAS/08.257(February).
Del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. European Journal of Pharmaceutical Sciences. 2008. p. 161-74.